Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1283 studies found for:    ( "January 30, 2012" : MAX ) [FIRST-RECEIVED-DATE] AND (lymphoma OR CLL [CONDITION ]) AND NOT myeloma [CONDITION] | Open Studies
Show Display Options
Download search resultsDownload the search results for:
( "January 30, 2012" : MAX ) [FIRST-RECEIVED-DATE] AND (lymphoma OR CLL [CONDITION ]) AND NOT myeloma [CONDITION] | Open Studies (1283 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Brazilian Network for Lymphoma Registry
Condition: Lymphoma
Intervention: Other: Observational, non-intervention
2 Not yet recruiting Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012
Conditions: Lymphoma;   Cancer
Intervention: Other: Show an increase in incidence of cancers in patients with synchronous lymphoma
3 Recruiting MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma
Condition: Lymphoma
Interventions: Device: magnetic resonance imaging;   Device: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18
4 Recruiting Clinical Cohort of Lymphoma Patients in Malawi
Conditions: Lymphoma;   Hematologic Malignancies
Intervention:
5 Recruiting Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)
Condition: Lymphoma
Intervention:
6 Recruiting Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Indolent Lymphoma
Interventions: Drug: Hu5F9-G4;   Drug: Rituximab
7 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
8 Recruiting Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Conditions: Mycosis Fungoides;   Lymphoma, Large B-cell, Diffuse
Intervention: Genetic: Cytogenetic and molecular studies
9 Recruiting Marginal Zone Lymphoma Cohort in Korea
Condition: Lymphoma, B-Cell, Marginal Zone
Intervention: Other: Rituximab
10 Not yet recruiting Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
Condition: Lymphoma
Intervention: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
11 Recruiting Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Drug: Brentuximab vedotin & Rituximab
12 Not yet recruiting Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Pembrolizumab
13 Recruiting Phase II Study of TAK228 in Relapsed Lymphoma
Condition: Lymphoma
Interventions: Drug: TAK228;   Other: Blood Sugar Testing
14 Recruiting Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Romidepsin + CHOP;   Drug: CHOP
15 Recruiting Detection and Characterization of Residual Masses in Lymphomas
Conditions: Hodgkin Lymphoma;   B-Cell Lymphoma
Intervention:
16 Recruiting Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
Condition: Classical Hodgkin Lymphoma
Intervention: Other: Digital Polymerase Chain Reaction
17 Recruiting Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
18 Recruiting Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
19 Recruiting A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Doxorubicin Hydrochloride;   Drug: Vinblastine;   Drug: Dacarbazine
20 Recruiting Genetic Study of Families With High Frequency of Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.